Ctrl Worx Watch List › Company
Cel Sci Corp (CVM): material weakness open 1,490 days
By Russell Tomoum, Ctrl Worx™. Built from its own SEC filings. How the Clock works.
Cel Sci Corp reported ineffective internal control over financial reporting because of a material weakness in 4 filings since Dec 27, 2022. It stated one or more material weaknesses in 12 more SEC filings that gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Jun 30, 2026.
Ctrl Worx Watch List™ status
On the ClockStill filing, and no annual report of its own says the weakness is fixed.
Checked against SEC EDGAR: Oct 29, 2026 · Entry #10079
Causes the company named
Not described · 12ITGC: user access · 4Entity-level and governance · 4Segregation of duties · 3Financial close and reporting · 2ITGC: change management · 2Complex or non-routine accounting · 1
Material weaknesses exist as previously reported in the 10-K for year ended September 30, 2025.
What the latest filing says
The Company’s Chief Executive Officer and Chief Financial and Operations Officer concluded that the Company’s disclosure controls and procedures were not effective as of June 30, 2026 due to the material weaknesses described in the Company’s Annual Report on Form 10-K for the year ended September 30, 2025. Changes in Internal Control over Financial Reporting There were no changes in the Company’s internal control over financial reporting that occurred during the three months ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. 34 Table of Contents [...]
From the controls section of the 10-Q filed Aug 14, 2026. Read the full filing on SEC EDGAR.
Company response: Cel Sci Corp can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.
Filings
| Filed | Form | Period | Controls | Causes | Filing |
|---|---|---|---|---|---|
| Aug 14, 2026 | 10-Q | Jun 30, 2026 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| May 15, 2026 | 10-Q | Mar 31, 2026 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| Feb 17, 2026 | 10-Q | Dec 31, 2025 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| Dec 29, 2025 | 10-K | Sep 30, 2025 | Not effective | Segregation of duties; Financial close and reporting; ITGC: user access; ITGC: change management; Entity-level and governance | EDGAR |
| Aug 14, 2025 | 10-Q | Jun 30, 2025 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| May 14, 2025 | 10-Q | Mar 31, 2025 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| Feb 14, 2025 | 10-Q | Dec 31, 2024 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| Jan 13, 2025 | 10-K | Sep 30, 2024 | Not effective | Segregation of duties; Financial close and reporting; ITGC: user access; ITGC: change management; Entity-level and governance | EDGAR |
| Aug 14, 2024 | 10-Q | Jun 30, 2024 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| May 15, 2024 | 10-Q | Mar 31, 2024 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| Feb 14, 2024 | 10-Q | Dec 31, 2023 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| Dec 21, 2023 | 10-K | Sep 30, 2023 | Not effective | ITGC: user access; Entity-level and governance | EDGAR |
| Aug 10, 2023 | 10-Q | Jun 30, 2023 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| May 12, 2023 | 10-Q | Mar 31, 2023 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| Feb 14, 2023 | 10-Q | Dec 31, 2022 | Material weakness stated, no ICFR conclusion | Not described | EDGAR |
| Dec 27, 2022 | 10-K | Sep 30, 2022 | Not effective | Segregation of duties; ITGC: user access; Entity-level and governance | EDGAR |
| Feb 12, 2021 | 10-Q | Dec 31, 2020 | Not effective | Complex or non-routine accounting | EDGAR |
Others on the Clock in the same industry
By SEC industry code: 2836, Biological Products, (No Diagnostic Substances), then related codes.
- Agentix Corp. (AGTX) · open since Mar 2023
- REPLIGEN CORP (RGEN) · open since Mar 2023
- Estrella Immunopharma, Inc. (ESLA) · open since Dec 2021
- ADAPTIN BIO, INC. (APTN) · open since Sep 2023
- FutureTech II Acquisition Corp. (FTII) · open since Sep 2023
Follow CVM for free
Get an email when Cel Sci Corp files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.
Want the next one the day it's filed?
MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.
Join the MW Pro waitlistLook up any company in Controls Radar™Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with Cel Sci Corp or the SEC. Not investment advice. Why you can rely on the Watch List.